The COVID-19 pandemic that became evident in the United States in early 2020 had a profound and disruptive effect upon cancer research and treatment, but the lessons learned can be used to improve healthcare delivery in multiple indications, according to the AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care that was released February 9th.
Although it’s difficult, when faced with a cancer diagnosis, it’s important to find the best health care facility to receive treatment. Improving the future of cancer tech, this posting looks at some of the most high-tech cancer hospitals in America.
NIH Awards Health Tech Companies with Grants to Develop Covid-19 Apps and Solutions
Academic Institutions, Algorithms, Artificial Intelligence, Contact Tracing, Coronavirus Disease (COVID-19) Pandemic, Covid-19 Data, Data Analytics, Digital Health, Influenza, Machine Learning, National Cancer Institute, National Institutes of Health, Phone Apps, San Francisco (UCSF), Smart PhonesThe U.S. National Institutes of Health (NIH) awarded seven companies and academic institutions grants to develop digital health technology to help with the Covid-19 pandemic.
AstraZeneca and Merck’s Combo Therapy Flunks Late-Stage Ovarian Cancer Trial
BRCA mutation, Business, Clinical Trials, Collaborations, Combination Therapies, DNA Damage Response (DDR), National Cancer Institute, NRG Oncology, PARP Inhibitors, Platinum-Sensitive Relapsed Ovarian Cancer, R&D, Vascular Endothelial Growth Factor (VEGF) InhibitorsAstraZeneca and Merck announced that the Phase III GY004 trial of cediranib in combination with Lynparza compared to platinum-based chemotherapy in platinum-sensitive relapsed ovarian cancer failed to meet the primary endpoint.
Cancer deaths in the United States fell 2.2% from 2016 to 2017 – the largest single-year drop ever recorded – fueled in large part by progress against lung cancer, the leading cause of cancer death, the American Cancer Society (ACS) reported.
U.S. President Donald Trump’s administration tapped National Cancer Institute Director Norman Sharpless to serve as acting commissioner for the Food and Drug Administration.